Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1370

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

BIOLOGICAL: barzolvolimab
OTHER: Standard of Care

Sponsor

Celldex Therapeutics